Cabozantinib for adults with previously treated neuroendocrine tumors
CaboLife: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients With Neuroendocrine Tumour
This study will see how cabozantinib works and how safe it is for adults with neuroendocrine tumors that have continued to grow after prior systemic treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ipsen Industry-sponsored |
| Drugs / interventions | cabozantinib |
| Locations | 28 sites (Graz and 27 other locations) |
| Trial ID | NCT07314164 on ClinicalTrials.gov |
What this trial studies
This observational study will follow about 150 adults with unresectable or metastatic, well-differentiated pancreatic or extra‑pancreatic neuroendocrine tumors who are starting cabozantinib as part of routine care. No extra procedures are required; investigators will collect data from standard medical visits, tests, and imaging to document tumor response, duration on treatment, side effects, and patient-reported quality of life. All participants must have received at least one prior systemic therapy (other than somatostatin analogues) and provide informed consent. The study is being conducted at regular hospitals and clinics in Germany and Austria to capture real-world use of cabozantinib.
Who should consider this trial
Good fit: Adults (18+) with unresectable or metastatic, well‑differentiated pancreatic or extra‑pancreatic neuroendocrine tumors who have had at least one prior systemic therapy (excluding somatostatin analogues) and whose physician has already decided to start cabozantinib are ideal candidates.
Not a fit: Patients currently enrolled in interventional clinical trials, those with contraindications to cabozantinib, or those with resectable disease or who have not had prior systemic therapy (other than somatostatin analogues) are unlikely to be eligible or benefit from joining this observational study.
Why it matters
Potential benefit: If successful, the study could help doctors understand how well cabozantinib controls tumor growth and what side effects patients experience in routine care, improving treatment decisions for future patients.
How similar studies have performed: Small clinical series and early-phase reports have suggested cabozantinib activity in some neuroendocrine tumors, but large randomized evidence is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants can join the study if they meet all of the following conditions: * Are 18 years or older and able to give informed consent. * Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study. * Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET). * Have already received at least one prior systemic therapy, other than somatostatin analogues. * Have signed a written informed consent form. Exclusion Criteria: Participants cannot join the study if: * They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study. * They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
Where this trial is running
Graz and 27 other locations
- Medizinische Universitaet Graz — Graz, Austria (Not_yet_recruiting)
- Kepler Universitaetsklinikum GmbH Linz — Linz, Austria (Not_yet_recruiting)
- MVZ am Klinikum Aschaffenburg — Aschaffenburg, Germany (Not_yet_recruiting)
- DRK Kliniken Berlin — Berlin, Germany (Not_yet_recruiting)
- Evangelische Lungenklinik Berlin — Berlin, Germany (Recruiting)
- Krankenhaus St. Joseph-Stift Bremen GmbH — Bremen, Germany (Recruiting)
- Klinikum Chemnitz — Chemnitz, Germany (Not_yet_recruiting)
- MVZ fuer Haematologie und Onkologie Koeln am Sachsenring — Cologne, Germany (Not_yet_recruiting)
- pioh Studien und Mangement GbR — Cologne, Germany (Recruiting)
- Gemeinschaftspraxis Haematologie - Onkologie — Dresden, Germany (Recruiting)
- Technische Univiersitaet (TU) Dresden — Dresden, Germany (Not_yet_recruiting)
- Universitaetsklinikum Essen — Essen, Germany (Not_yet_recruiting)
- Krankenhaus Nordwest — Frankfurt, Germany (Not_yet_recruiting)
- Uniklinikum Frankfurt — Frankfurt am Main, Germany (Not_yet_recruiting)
- Universitaetsklinikum Giessen-Marburg — Giesen, Germany (Not_yet_recruiting)
- Universitaetsmedizin Goettingen — Goettigen, Germany (Recruiting)
- Asklepios Kliniken Hamburg — Hamburg, Germany (Not_yet_recruiting)
- Universitaetsklinikum Hamburg-Eppendorf — Hamburg, Germany (Not_yet_recruiting)
- Studienzentrum UnterEms — Leer, Germany (Not_yet_recruiting)
- MVZ Leipzig Mitte, MVZ Delitzsch — Leipzig, Germany (Not_yet_recruiting)
- Universiteatsmedizin Leipzig — Leipzig, Germany (Not_yet_recruiting)
- RKH Kliniken Ludwigsburg-Bietigheim gGmbH — Ludwigsburg, Germany (Recruiting)
- Philipps-Universitaet Marburg — Marburg, Germany (Not_yet_recruiting)
- Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR — Minden, Germany (Not_yet_recruiting)
- MVZ Muelheim an der Ruhr GmbH — Mülheim, Germany (Not_yet_recruiting)
- Universitätsklinikum Tuebingen — Tübingen, Germany (Recruiting)
- Medizinische Studiengesellschaft Nord-West — Westerstede, Germany (Recruiting)
- Universitaetsklinikum Wuerzburg — Würzburg, Germany (Recruiting)
Study contacts
- Study coordinator: Ipsen Clinical Study Enquiries
- Email: clinical.trials@ipsen.com
- Phone: See e mail
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.